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Summary
The development of spontaneous insulin-dependent
diabetes mellitus is preceded by the organization of
tertiary lymphoid organ (TLO) in situ, but its role in
the development of tissue destruction and the cyto-
kines that control such structures have not been fully
defined. We have now observed that TNF superfamily
14 (TNFSF14) is upregulated in aged nonobese dia-
betic (NOD) pancreas with the appearance of TLO.
Blockade of TNFSF14 signaling caused a substantial
reduction in the expression of lymphotoxin b receptor
(LTbR)-controlled migration factors within the islets
and disrupts organization of tertiary structures, lead-
ing to prevention of diabetes. Consistently, enhancing
LTbR signaling by transgenic expression of TNFSF14
in the islets of NOD mice rapidly promoted de novo
formation of local TLO, resulting in diabetes, even in
the absence of draining lymph nodes (LN). Thus, the
TNFSF14-LTbR pathway appears to be critical in the
development and maintenance of TLO for the onset
of diabetes.
Introduction
Although de novo organization of tertiary lymphoid or-
gan (TLO) is known to precede the development of
a number of human autoimmune diseases (Aloisi,
2006; Ruddle, 1999), its role in the development of auto-
immune diseases is unclear. Insulin-dependent diabe-
tes mellitus (IDDM) is a T cell-mediated autoimmune dis-
ease in which the insulin-secreting b cells are selectively
destroyed (Bach, 1994; Tisch and McDevitt, 1996). Stud-
ies performed in nonobese diabetes (NOD) mice have
revealed that the influx of cellular infiltrates migrate to
the pancreas starting at 4–6 weeks of age (Bach and Ma-
this, 1997; Delovitch and Singh, 1997; Green and Flavell,
1999; Ludewig et al., 1998; Tisch and McDevitt, 1996),
but it is only with continued progressive inflammation
that an organized lymph node-like follicular structure
will develop, usually over 2–3 months, culminating in
the development of IDDM. In diabetes, the peri-insular
infiltration organizes into TLO with cellular infiltrates
and increased expression of key chemokines and adhe-
sion molecules (Hanninen et al., 1993; Hjelmstrom et al.,
2000; Yang et al., 1997). Although the formation of TLO
*Correspondence: yfu@uchicago.eduis a prototypic feature of chronic progressive inflamma-
tion (Aloisi, 2006; Ruddle, 1999), the molecular mecha-
nisms by which the TLOs are formed and importantly
their role in the pathogenesis of IDDM remains to be
demonstrated.
The initiation of the autoimmune response in NOD in
the draining lymph node (LN) is essential for priming
and clonal expansion of autoreactive T cells poised for
islet destruction (Hoglund et al., 1999). The removal of
the pancreatic draining LNs prior to a critical time point
of autoreactive T cells priming prevents IDDM in NOD
mice, demonstrating the absolute requirement of drain-
ing LNs in the initial stages of disease induction (Gagner-
ault et al., 2002; Levisetti et al., 2004). Initiation of the dis-
ease process in the draining LN is not sufficient,
however, as shown by the fact that diabetogenic T cells
isolated from the draining LNs of 10-week-old NOD mice
have markedly reduced efficiency for transferring the
disease to NOD SCID recipients compared to the spleen
(Jaakkola et al., 2003). Similarly, disease incidence is un-
changed in NOD mice deprived of pancreatic draining
LNs or spleen at 10 weeks compared to control mice
with intact secondary lymphoid structures (Gagnerault
et al., 2002). The diminished importance of the LNs
and the spleen during the effector phase of disease sug-
gests that alternative lymphoid structures may take over
their function. However, it is unclear why draining LNs
become irrelevant after the initial priming, how the autor-
eactive response is sustained in their absence, and
whether the priming of T cells in an alternative location
is a prerequisite for the generation of a sufficiently ro-
bust autoimmune repertoire for the development of
IDDM.
Membrane lymphotoxin (LT) was initially found to be
essential for the development of secondary lymphoid
tissues (Fu and Chaplin, 1999). LT, and to a lesser de-
gree tumor necrosis factor (TNF), is sufficient for TLO
as well as for the maintenance of the lymphoid struc-
tures (Luther et al., 2000; Ngo et al., 1999; Ruddle,
1999). Wild-type (wt) mice treated with lymphotoxin b re-
ceptor-immunoglobulin fusion protein (LTbR-Ig) exhibit
reduced chemokines and adhesion molecules inside
secondary lymphoid tissues, leading to alterations in
the lymphoid microenvironment as well as a reduction
in the cellularity in the lymph nodes (Browning et al.,
2005; Fu and Chaplin, 1999; Mackay and Browning,
1998; Mackay et al., 1997; Ngo et al., 1999; Wu et al.,
1999). LTbR-Ig has been shown to alleviate various mu-
rine models of autoimmune diseases such as rheuma-
toid arthritis, colitis, experimental autoimmune enceph-
alomyelitis (EAE) (which is independent of pertuss
toxins), and late stage of type 1 diabetes (Fava et al.,
2003; Gommerman et al., 2003; Mackay et al., 1998;
Wu et al., 2001). Although LT is thought to be responsi-
ble for TLO, a recent study indicates that the chronic in-
fection can trigger the same organization in the absence
of LT (Moyron-Quiroz et al., 2004). TNF superfamily 14
(TNFSF14), another ligand for LTbR that is commonly
known as lymphotoxin-like inducible protein that com-
petes with glycoprotein D for binding herpesvirus entry
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500Figure 1. LTbR-Ig Blockade Does Not Perturb Priming, but Reduces Expression of Migration Factors
(A) CFSE-labeled 20 million NOD-BDC2.5 (6- to 7-week-old) splenocytes were adoptively transferred to sublethally irradiated 10-week-old NOD
recipients treated with 100 mg of either control h-IgG (Solid) or LTbR-hIgG (Green) on day27 and day 0. CFSE dilution was determined 72 hr after
transfer by FACS analysis after gating on Vb4+CD4+ lymphocytes. The data are representative of three independent experiments.
(B) Real-time PCR analysis of cDNA prepared from the pancreatic islets of 10-week-old NOD mice 1 week after last treatment of three weekly
treatment with 100 mg of control-IgG or LTbR-IgG. Relative abundance of mRNA of BLC and SLC determined.
(C) 10-week-old NOD mice were treated with 100 mg of control Ig (left) or LTbR-Ig (right) once weekly for 3 weeks. The spleens (top) and the pan-
creata (bottom) were collected 10 days after the end of the treatment. The splenic sections were stained with B220 (brown) and anti-MAdCAM-1
(purple), whereas pancreatic sections were stained with anti-CD3 (brown), anti-MAdCAM-1 (purple), and anti-insulin (red). Original magnification:
3200.
(D) Sublethally irradiated NOD female mice were injected i.v. with 2 3 107 splenocytes from diabetic NOD mice and treated with a single i.p.
injection of 100 mg of Anti-MAdCAM-1 (MECA367), LTbR-Ig, or human Ig. The incidence of diabetes was monitored.mediator on T cells (LIGHT), can also partially replace
the role of LT for the development and maintenance of
the lymphoid microenvironment inside the spleen (Gom-
merman and Browning, 2003; Wang et al., 2002; Ware,
2005). The contribution of LIGHT in the development of
TLO during chronic inflammation is, however, unknown.
In this study, we uncover the central role of the LIGHT-
LTbR in organizing TLO at sites of chronic autoimmune
inflammation and the key role these structures play
in tipping autoimmunity toward active autoimmune
destruction.
Results
LTbR-Ig Treatment Does Not Limit Priming
in the Draining LN
We have previously reported that LTbR-Ig treatment in
prediabetic NOD mice prevents the development of
IDDM, but the mechanism remains unclear (Wu et al.,
2001). LTbR-Ig binds not only to heterotrimic membrane
bound LTa1b2 (LTb) on T cells, but also to LIGHT, a cos-timulatory molecule expressed on T cells and dendritic
cells (DC). Because the onset of diabetes is predomi-
nantly T cell mediated, it is possible that LTbR-Ig blocks
activation of autoreactive T cells primed in the draining
LN (DLN). To rule out this possibility, we adoptively
transferred 2 3 107 CFSE-labeled splenocytes from 6-
to 7-week-old NOD-BDC2.5 T cell receptor (TCR) trans-
genic T cells to 10-week-old prediabetic NOD recipients
that had been treated with LTbR-Ig or control-Ig.
BDC2.5 T cells are clonotypic TCRs specific for islet an-
tigens. It has been previously reported that adoptively
transferred naive BDC2.5 CD4+ T cells are primed at
the pancreatic LNs of NOD recipients 3 days after trans-
fer (Hoglund et al., 1999). Analysis of the donor cells iso-
lated from the pancreatic draining LN 72 hr after adop-
tive transfer revealed that priming and homing to the
DLN remained unperturbed by LTbR-Ig treatment
(Figure 1A). These data suggest that the prevention of
IDDM by soluble LTbR treatment may be due to mecha-
nisms other than inhibited trafficking and priming of
pathogenic T cells in the DLN.
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of Chemokines and Adhesion Molecules
inside the Islets
An alternative explanation for the prevention of IDDM via
LTbR-Ig administration could be through the prevention
of activated lymphocyte trafficking to peripheral target
organ. T cells and DCs migrate to the pancreas in re-
sponse to local CCL21 (SLC) and CCL19 (BLC) expres-
sion (Chen et al., 2002; Luther et al., 2000), and homing
of early diabetogenic effector lymphocytes to the islets
is also dependent on MAdCAM-1 (Yang et al., 1997).
To determine whether blocking LTbR signaling disrup-
ted expression of these key lymphocyte migrational
cues to the pancreas, real-time PCR of purified pancre-
atic islets was performed on LTbR-Ig- and control-
Ig-treated NOD mice. Mice were treated with 100 mg of
either protein once weekly for 3 weeks and sacrificed
for analysis 1 week after the last treatment. Relative
analysis revealed approximately 80% reduction in the
mRNA expression of SLC and to a lesser extent of
BLC expression observed in the islets of LTbR-
Ig-treated mice compared to that of controls (Figure 1B).
Furthermore, immunohistochemical staining of the
spleen and pancreas of NOD mice treated with either
100 mg of LTbR-Ig or human-Ig once a week for 3 weeks
and sacrificed for analysis 1 week after the last treat-
ment revealed the absence of MAdCAM-1 staining in
the LTbR-Ig-treated group. This was in contrast to the
abundant staining seen in splenic marginal zones and is-
lets of the control group (Figure 1C, top). Consistently,
immunohistochemical staining, with MAdCAM-1, CD3,
and insulin, of the pancreatic islet section revealed de-
creased MAdCAM-1 expression around islets that typi-
cally correlated with fewer pathogenic CD3+ T cell infil-
trations in the LTbR-Ig-treated group compared to the
control group (Figure 1C, bottom). These findings indi-
cate that the expression of MAdCAM-1, SLC, and BLC
in the pancreas is markedly perturbed by the blockade
of LTbR signaling, resulting in the inhibition of cellular
trafficking to the islets. The downregulation of these
key adhesion molecule and chemokines in the local mi-
croenvironment may be sufficient to prevent disease de-
velopment even in the presence of primed autoreactive
T cells.
To demonstrate that the reduction of LT-mediated
MAdCAM-1 expression sufficiently contributes to the re-
duction of pathogenic insulitis, we transferred 23 107 T
cells from newly identified diabetic NOD mice (<2 weeks)
into sublethaly irradiated 8- to 10-week-old NOD recipi-
ents that were concomitantly treated with 100 mg of
either anti-MAdCAM-1 (MECA367), LTbR-Ig, or control-
Ig once per week for 3 weeks. Then the mice were
monitored for incidence of diabetes. Treatment with
anti-MAdCAM-1 recapitulated, albeit to a lesser degree,
the preventive effects seen with LTbR-Ig treatment
(Figure 1D). Taken together, these data suggest that
downregulation of LTbR-dependent adhesion mole-
cules and chemokines within the pancreatic islets may
contribute to the LTbR-Ig-mediated prevention of IDDM.
Involvement of LIGHT in the Development of IDDM
Stimulation of membrane LTbR on the stromal cells for
the expression of chemokines and MAdCAM-1 can
occur through two known ligands: LTb and LIGHT(Gommerman and Browning, 2003; Wang et al., 2002;
Ware, 2005). Both ligands are predominantly expressed
on activated T cells, but LIGHT can also signal through
another TNF receptor family member, HVEM. To unravel
the contribution of one or both ligands to the prevention
of disease, we treated prediabetic 10-week-old NOD
mice with 100 mg of either LTb antibody to selectively
block LT, HVEM-Ig to selectively block LIGHT, LTbR-Ig
to block both LTb and LIGHT, or control-Ig. The mice
were injected weekly for 3 weeks and then monitored
for incidence of diabetes for 32 weeks. We found that
whereas blocking membrane LT had marginal effects
in preventing IDDM, blocking LIGHT greatly prevented
disease progression (Figure 2A). To exclude the
possibility that blocking LIGHT-HVEM merely inhibited
costimulatory activation of pathogenic T cell and subse-
quently prevented diabetes, we examined H&E-stained
paraffin sections of pancreatic tissues from HVEM-
Ig- or control-Ig-treated NOD mice. Our analysis
revealed that HVEM-Ig treatment reduced insulitis in
the pancreatic islets by approximately 50% overall com-
pared to the controls (Figure 2B). There was more appre-
ciable reduction of insulitis in the islets with greater than
50% infiltration score in the HVEM-Ig-treated group
(Figure 2B). These results suggest that blocking LIGHT
interaction with its cognate ligands, by LTbR or HVEM,
contributes in ameliorating diabetes pathogenesis.
LIGHT Expression in the Pancreas Accelerates
Insulitis and IDDM Onset
We attempt to tease out the mechanism by which LIGHT
signaling through its cognate receptors regulates T cell-
mediated destruction of b islet cells. First, to demon-
strate that the pathological amount of LIGHT in the local
microenvironment increases in association with disease
progression in the murine model, we measured LIGHT
mRNA expression in the pancreas of 5-week-old NOD,
prediabetic 20-week-old NOD, and 12-week-old B6
mice as controls. We found that the relative expression
of LIGHT in the pancreas increased with age in NOD
mice, which in turn correlates with exacerbated insulitis
(Figure 3A and data not shown).
Although the age-dependent increase of LIGHT
mRNA expressions in the local environment revealed
a correlation with the development of diabetes, it did
not elucidate the function of LIGHT in disease induction.
To further demonstrate the consequence of LIGHT on
the islets for propagating the disease, we decided to
generate transgenic mice expressing LIGHT in the b cells
under the control of the rat insulin promoter (RIP) in the
NOD background (see Figure S1 in the Supplemental
Data available with this article online). Southern blot
analysis as well as RT-PCR of relative LIGHT mRNA ex-
pression on the islets of the transgenic (tg) mice were
used to detect the presence of the transgene and con-
firm expression of LIGHT, respectively (Figure S1 and
data not shown). The homozygous tg mice we gener-
ated possess only one copy of the transgene, thus bear-
ing a closer physiological expression of pancreatic
LIGHT in the pancreas of aged NOD mice. In this model,
RIP-LIGHT-NOD mice developed the disease at a much
earlier age with complete onset compared to the NOD
controls (Figure 3B). The disease acceleration was
more evident in LIGHT transgenic NOD male mice, as
Immunity
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(A) Blockade of LIGHT via HVEM-Ig prevents the development of IDDM in NOD mice. 10-week-old NOD mice were treated with 100 mg Control Ig,
LTbR-Ig, HVEM-Ig, or LTb Ab once a week consecutively for 3 weeks. Incidence of diabetes evaluated for 32 weeks.
(B) Pancreata stained with H&E 1 week after last treatment with HVEM-IgG or control-IgG. Individual islets from five mice per group were as-
signed scores for insulitis as measured by cellular infiltration. Original magnification: 3200.shown by the fact that most developed disease before
18 weeks, whereas none had IDDM in male control;
100% developed the disease before 23 weeks while
only 10% developed the disease in the male controls
(Figure 3B).
The development of diabetes is often preceded by in-
flammatory insulitis with subsequent formation of an or-
ganized LN-like structure around the islets (Luther et al.,
2002; Ruddle, 1999). To investigate whether the higher
incidence of IDDM at an early age in the RIP-LIGHT-
NOD mice was associated with such trademark
characteristics, the pathology of pancreatic tissue was
investigated. As anticipated, 4- and 6-week-old RIP-
LIGHT-NOD mice displayed severe infiltrates of mono-
nuclear cells of varying sizes, and the large cellular
infiltrates in the islets resembled those observed in mice
with insulitis (Figure 3C). Minimal infiltration was evident
in age-matched NOD mice, although by 6 weeks of age
we began to see increased perinsulitis around the islets
(Figure 3C). However, we observed that the degree of
insulitis in the 4-week-old RIP-LIGHT-NOD mice resem-
bled that of 10-week-old NOD mice, suggesting that
local LIGHT expression facilitates homing of activated
T cells to the islets.Islets expressing LT are sufficient to induce TLO (Rud-
dle, 1999). Our initial observation of increased lympho-
cytic infiltration to the islets upon LIGHT expression
leads us to hypothesize that LIGHT signaling through
its receptors can also induce de novo formation of
TLO in the pancreas, similar to secondary lymphoid
organs. Histological analysis of pancreatic tissue from
5-week-old RIP-LIGHT-NOD mice stained with Thy1.2+
and B220+ showed the presence of an organized T-B
cell zone that closely mimicked those found in second-
ary lymphoid follicles (Figure 3D). Furthermore, similar
structured T-B cell zone was observed in the islets of
20-week-old prediabetic NOD mice, yet was conspicu-
ously absent in 5-week-old NOD mice (Figure 3D and
data not shown). In addition, both 4- to 5-week-old
RIP-LIGHT-NOD mice and prediabetic 20-week-old
NOD mice had elevated pancreatic expression of SLC
mRNA, a well-characterized chemokine marker known
to be critical for the formation of TLO (Fan et al., 2000;
Hjelmstrom et al., 2000; Luther et al., 2000), when com-
pared to 4- to 5-week-old NOD mice (Figure 3E). Thus,
the increase in pancreatic SLC expression, coupled
with the presence of TLO in the islets, indicates that
LIGHT signaling with its receptors, likely through LTbR,
The Role of Lymphotoxin Receptor Signaling in IDDM
503Figure 3. LIGHT Expression on the Pancreatic Islets Exacerbates Diabetes Onset
(A) Real-time PCR analysis of cDNA prepared from pancreas of 5- or 20-week-old NOD and B6 mice. Data are representative of two experiments.
(B) Incidence of diabetes observed for RIP-LIGHT-NOD females and RIP-LIGHT-NOD males with respective NOD wt controls. Mice were con-
sidered diabetic with blood glucose concentration >250 mg/dL for two consecutive weeks.
(C) H&E staining of pancreata of 4- or 6-week-old female RIP-LIGHT-NOD and NOD wt mice. Original magnification: 3200.
(D) LIGHT expression on the islets induces TLO similar to the secondary lymphoid organs. Immunohistochemical staining of pancreatic islets of
5-week-old RIP-LIGHT-NOD mice or 20-week-old prediabetic NOD mice; anti-Thy1.2 (blue) and anti-B220 (brown). Original magnification:3200.
(E) Real-time PCR analysis of SLC expression in pancreas of 5- or 20-week-old NOD mice and 5-week-old RIP-LIGHT-NOD mice. The data are
representative of two experiments.can induce formation of TLO in the pancreas of NOD
mice, invariably promoting the development of IDDM.
Naive T Cells Are Attracted to TLO
The hallmark characteristic of secondary lymphoid
structures is their exquisite ability to recruit circulating
naive lymphocytes and elicit priming and subsequent
clonal expansion of antigen-specific T cells (Butcher
and Picker, 1996; Cyster, 1999). To confirm that the
LIGHT-mediated TLO in the pancreas possess func-
tional characteristics ascribed to secondary lymphoid
follicles, we transferred 2 3 107 naive CFSE-labeled
splenocytes from 7- to 8-week-old BDC2.5 tg mice
into sublethally irradiated 4-week-old RIP-LIGHT-NOD
and age-matched NOD controls. Immunofluroescent
staining of pancreatic tissues at 48 hr after transfer re-
vealed that LIGHT-induced TLO enabled the recruitment
of CFSE+ cells to the local islets, whereas only few such
cells were detected in age-matched NOD mice
(Figure 4A). Our FACS analysis of pancreatic islets, pan-
creatic DLN, and spleen cells isolated at 24 hr after
transfer revealed a substantial population of undiluted
CFSE (at 0 cycle)-labeled naive T cells recruited to
both the spleen and the pancreatic DLN of all three
groups (Figure 4B). However, only the islets of RIP-
LIGHT-NOD and 16-week-old WT-NOD mice, which we
had previously shown in our earlier data to clearly pos-
sess TLO in the islets, contained substantial numbers
of adoptively transferred T cells (Figure 4B). Further-more, at 72 hr after transfer, continued CFSE dilution,
which is indicative of further proliferation, was present
in the islets of RIP-LIGHT-NOD mice and 16-week-old
WT-NOD mice, yet notably absent in young 8-week-
old WT-NOD mice. Expectedly, all three groups had pro-
liferation in the pancreatic DLNs by 72 hr after transfer
(Figure 4B). Stronger proliferation in the islets than in
the draining LN of both 16-week-old NOD mice and 8-
week-old RIP-LIGHT-NOD mice may suggest that the is-
lets play a greater role in priming and expanding autor-
eactive T cells.
To further demonstrate that the cells were proliferat-
ing in situ, the recipients were pulsed with 100 mg of 5-
bromo-2-deoxyuridine (BrdU) via i.p. at 72 hr after adop-
tive transfer as described above. The pancreatic tissue
was harvested 24 hr later for immunohistology. The se-
rial sections of pancreatic tissue were then visualized
with the CFSE+ cells or immunostained with anti-BrdU
(brown) and counterstained with hemotoxylin. Our data
clearly show that the CFSE+ T cells migrate to the islets
of RIP-LIGHT-NOD and the prediabetic 16-week-old
NOD mice, and these cells proliferate in situ, as evi-
denced by BrdU-positive staining within the islets
(Figure 5A). These results demonstrate that TLO present
in the islets of RIP-LIGHT-NOD and prediabetic NOD
mice resembles secondary lymphoid structures in ap-
pearance and function, specifically in the recruitment
of naive T cells to the target site for activation and
proliferation.
Immunity
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(A) Immunofluorescence staining of CFSE-labeled BDC2.5 splenocytes (2 3 107 cells) adoptively transferred to 4-week-old NOD wt and age-
matched RIP-LIGHT-NOD NOD mice. Tissue harvested and fixed 48 hr after cell transfer. Original magnification: 3100.
(B) CFSE-labeled BDC2.5 splenocytes (2 3 107 cells) were adoptively transferred to sublethally irradiated 8-week-old RIP-LIGHT-NOD
mice, 8-week-old NOD mice, and prediabetic 16-week-old NOD mice. Islets, PDLN, and spleen were collected 24 hr and 72 hr after adoptive
transfer and observed for CFSE dilution on Vb4+CD4+ gated lymphocytes. Data are a representation of three experiments with three mice per
group.To ensure that the infiltration and proliferation of T
cells in TLO in the islets can translate into the pathogen-
esis of IDDM, splenocytes from 2 3 107 naive BDC2.5
splenocytes were transferred into sublethally irradiated
4-week-old RIP-LIGHT-NOD and NOD mice (Figure 5B).
50% of the RIP-LIGHT-NOD mice developed diabetes
2 weeks after transfer of BDC2.5 cells, and by 5 weeks
after transfer, 100% of the RIP-LIGHT-NOD mice have
developed diabetes. In contrast, none (0%) of the irradi-
ated NOD mice developed diabetes even 15 weeks after
transfer (Figure 5B). To demonstrate that the observed
incidence of diabetes was not caused by the endoge-
nous population of autoreactive T cell in the irradiated
LIGHT-expressing mice, 4-week-old RIP-LIGHT-NOD
mice were sublethally irradiated and observed for
possible disease onset. As we expected, in the absence
of adoptively transferred cells, irradiated RIP-LIGHT-
NOD mice did not develop diabetes (Figure 5B).When the 2 3 107 naive BDC2.5 splenocytes were
adoptively transferred to irradiated 14- to 16-week-old
prediabetic NOD mice (not younger NOD mice), which
we have shown earlier to possess TLO in the islets,
more than 90% of mice developed IDDM by 12 weeks af-
ter transfer, whereas none (0%) developed in mice lack-
ing cell transfer (Figure 5C). The incidence of diabetes
development, in this antigen-specific adoptive transfer
model, was dependent on LTbR signaling, as shown
by the fact that the abrogation of the ectopic structure
in RIP-LIGHT-NOD mice by weekly treatment of mice
with 100 mg of LTbR-Ig starting at 3 weeks of age for
3 weeks substantially precluded disease onset (data
not shown). Earlier, we also provide evidence that the
development of IDDM can also be blocked by the use
of LTbR-Ig in older (10-week-old) prediabetic WT-NOD
mice (Figure 2A). Thus, these results demonstrate the
necessity of LTbR signaling-mediated TLO in diabetes
The Role of Lymphotoxin Receptor Signaling in IDDM
505Figure 5. Naive T Cells Are Recruited to TLO and Proliferate In Situ, Inducing Diabetes Onset
(A) BDC2.5 splenocytes (2 3 107 cells) were CFSE labeled and adoptively transferred i.v. to sublethally irradiated 8-week-old NOD, 8-week-old
RIP-LIGHT-NOD, and 16-week-old prediabetic NOD mice. Mice were injected with 100 mg of BrdU i.p. at 72 hr after adoptive transfer and pan-
creas was harvested 24 hr after BrdU injection. Top panel is immunofluroescence of CFSE-labeled (green) naive BDC2.5 splenocytes. The bot-
tom panel is immunohistochemical staining of BrdU (brown) and counterstained with hematoxylin. Each CFSE-labeled tissue section located on
the top panel corresponds to its BrdU tissue staining as a serial section. Original magnification: 3200.
(B) BDC2.5 splenocytes (23 107 cells) were adoptively transferred to sublethally irradiated 4-week-old RIP-LIGHT-NOD mice and age-matched
NOD wt and monitored for incidence of diabetes. Sublethally irradiated RIP-LIGHT-NOD mice without cell transfer included as controls for in-
cidence of diabetes.
(C) BDC2.5 splenocytes (2 3 107 cells) were transferred to sublethally irradiated prediabetic 14- to 16-week-old NOD wt mice and observed for
incidence of diabetes.progression, because the transfer of naive T cells to
young (4-week-old) NOD mice with intact DLN could
not induce the disease, yet the transfer of naive tg cells
to older NOD mice (14- to 16-week-old) was able to
cause IDDM.
Tertiary Lymphoid Structure Is Sufficient to Replace
Draining Lymph Node
Pancreatic DLN (PDLN) is crucial to prime autoreactive T
cells in NOD mice beginning at 3–4 weeks old, because
the absence of PDLN protected the mice from develop-
ing diabetes (Gagnerault et al., 2002). The same protec-
tion was not conferred when the PDLN were ablated at
10 weeks (Gagnerault et al., 2002). We wanted to explore
whether the LIGHT-mediated TLO is sufficient to elicit
diabetes even in mice lacking PDLN from 3 weeks of
age. We propose that in the presence of TLO, even
mice lacking DLN could sufficiently develop the disease,
because naive T cells can be recruited to the local
environment and get primed and proliferate there. To
demonstrate this, we surgically excised the PDLN inRIP-LIGHT-NOD and WT-NOD mice at 3 weeks of age
and monitored for incidence of diabetes for over 30
weeks. We found that RIP-LIGHT-NOD mice ablated of
their PDLNs at 3 weeks were still able to develop
IDDM in both males (100%) and females (88%), when
only 10% of NOD females and none (0%) of NOD males
developed IDDM (Figure 6A).
To formally visualize that TLO can recruit naive T cells
into the lesion and proliferate in situ, even in the absence
of the draining LN, we transferred CFSE-labeled naive
BDC2.5 splenocytes (2 3 107 cells) to 6-week-old RIP-
LIGHT-NOD and aged matched NOD mice that had their
PDLNs removed. Pancreas tissue was collected and
frozen 96 hr after transfer. Naive CFSE-labeled BDC2.5
T cells migrated to the islets even in the absence of
PDLN for RIP-LIGHT-NOD mice, whereas infiltrating
cells was absent in PDLN-ablated NOD controls (Fig-
ure 6B). Similarly, only 4-week-old RIP-LIGHT-NOD
mice with PDLN removed showed infiltrating inflamma-
tory cell near the islets in conjunction with in situ prolif-
eration, indicated by the Ki-67 immunohistochemical
Immunity
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(A) PDLNs in 3-week-old female or male RIP-LIGHT-NOD mice were surgically excised and spontaneous diabetes development was observed
over time.
(B) CFSE-labeled BDC2.5 splenocytes (23 107 cells) were adoptively transferred to sublethally irradiated 5-week-old NOD and RIP-LIGHT-NOD
mice that have had the DLNs removed. Pancreatic tissues were collected 96 hr after transfer of cells for immunofluoresence staining; insulin (red)
and CFSE-labeled transferred cells (green). Original magnification: 3200.
(C) H&E staining of pancreata for 4-week-old female RIP-LIGHT-NOD and NOD mice with PDLN removed.
(D) Sublethally irradiated 36-week-old nondiabetic NOD mice with PDLN removed were adoptively transferred with BDC2.5 splenocytes
(2 3 107 cells). Control group did not receive cell transfer. Diabetes development was observed weekly after adoptive transfer.staining, whereas this observation was absent in NOD
controls (Figure 6C and data not shown).
The removal of pancreatic draining LNs in young mice
caused them to develop insulitis, albeit to a lesser
degree when compared to mice with intact LNs (Gagner-
ault et al., 2002). To formally demonstrate that TLO pres-
ent in prediabetic older NOD mice can also prime naive T
cells and induce diabetes even in the absence of DLNs,
we adoptive transferred naive BDC2.5 (2 3 107 cells) to
sublethally irradiated nondiabetic older NOD mice with
PDLN removed. Importantly, all the mice (100%) re-
sulted in diabetes onset by 4 weeks post adoptive trans-
fer, whereas none (0%) of age-matched PDLN-ablated
NOD controls lacking cell transfer developed diabetes
(Figure 6D). As shown earlier, transfer of cells fromBDC2.5 mice into younger (4-week-old) NOD mice failed
to induce IDDM even when priming occurs unhindered,
largely due to the nonappearance of TLO. Collectively,
our data suggest that TLO may effectively and suffi-
ciently replace the function of secondary lymphoid tis-
sues for the eventual development of IDDM.
Discussion
The development of spontaneous IDDM is often antici-
pated by the de novo formation of TLO. The contribution
of these structures to disease had been unclear. This
study suggests a critical role for these structures in am-
plifying the adaptive response in situations where effec-
tive priming of T cells is hindered because of the paucity
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507of antigens reaching the secondary lymphoid organs.
This phenomenon may be attributed to the complexity of
the tissue stroma, which can prevent migration of some
antigens to the draining LN (Spiotto et al., 2002), or a fail-
ure of indirect presentation upon reaching the LN
(Spiotto et al., 2004). Direct recruitment of naive T cells
into the lesion permits maximum exposure to highly con-
centrated and diversified antigens and enhances the
activation of more responsive T cells. Therefore, the
role of draining LN is diminished as the lesion becomes
chronic and TLO increasingly play a role in recruiting and
activating T cells, leading to final destruction of tissue.
Membrane LT was initially found to be essential for the
development of secondary lymphoid tissues (Browning
et al., 2005; Fu and Chaplin, 1999; Mackay and Brown-
ing, 1998; Mackay et al., 1997; Ngo et al., 1999; Wu
et al., 1999). The use of LTbR-Ig fusion protein has
been shown to alleviate various autoimmune diseases
(Fava et al., 2003; Gommerman et al., 2003; Mackay
et al., 1998; Wu et al., 2001). It has been assumed, but
not proven, that LT is the essential ligand for the devel-
opment of TLO. However, a recent study indicates that
chronic infection can trigger the formation of TLO in
the absence of LT, raising the possibility that other mol-
ecules may replace the role of LT in some conditions
(Moyron-Quiroz et al., 2004). Our study suggests that
LIGHT may promote the formation of TLO independently
of LT. Not only is LIGHT expression prominent in the TLO
of aged NOD mice, but blockade of LIGHT by HVEM is
effective in reversing insulitis. However, it remains to
be determined whether blocking via fusion proteins
may function on multiple levels: not only at the local ec-
topic structure, but also by the disruption of other cellu-
lar components involved in disease induction. Consis-
tently, LIGHT rescues disrupted secondary lymphoid
structures caused by the absence of LT (Wang et al.,
2002), and overexpression of LIGHT at local sites stimu-
lates the formation of TLO leading to the development of
IDDM. Our LIGHT tg mice illustrate the efficiency by
which an upregulated LIGHT expression in the periph-
eral tissue can contribute not only to the lymphoid struc-
ture but also to the recruitment of naive lymphocytes in
the target tissue. It would be interesting to observe
whether LIGHT-LTbR signaling plays a similar role in
other T cell-mediated autoimmune diseases.
The importance of the secondary lymphoid organs in
the initiation and maintenance of autoimmune disease,
in particular IDDM, has been suggested by recent stud-
ies. Priming of autoreactive T cells in pancreatic draining
LNs occurs early in the disease course (Gagnerault et al.,
2002; Hoglund et al., 1999; Levisetti et al., 2004). How-
ever, removal of the draining LN during the effector
phase of the disease fails to inhibit diabetes progression
(Gagnerault et al., 2002). Because disease progress rap-
idly becomes independent of these draining LNs, it is
unclear how the autoreactive response becomes self-
sustained. Our study shows that in the case of IDDM,
a TLO mediated by LIGHT-LTbR signaling develops in
the pancreas as the NOD mice age, and this ectopic
structure may replace the function of the draining LN
for local activation of immune cells. Consistent with
data shown by others, we found that resection of
PDLN prevented diabetes in NOD mice only if performed
prior to 3 weeks of age. Furthermore, the transfer of na-ive transgenic cells was able to provoke disease in aged
nondiabetic PDLN-ablated NOD mice. This suggests
that the presence of TLO in the pancreas is sufficient
for the recruitment of naive cells and their initial priming,
even in the absence of DLN.
Although TLO via LTbR signaling can supersede the
function of DLNs after initial priming, cell recruitment
alone is not sufficient for autoimmune disease. Earlier
studies with RIP-TNFa, RIP-LT Tg, or RIP-SLC and
BLC mice in B6 models show clear formation of such
structure as well as massive cellular infiltrates, but no
tissue destruction (Drayton et al., 2002; Luther et al.,
2000; Picarella et al., 1992, 1993). It is likely that ex-
panded autoimmune repertoires as a result of defective
central tolerance or enhanced local costimulation may
be required. For example, RIP-TNFa x RIP-B7 double
transgenic mice lead to IDDM whereas neither single-
transgenic mice does (Guerder et al., 1994). The pro-
found exacerbated phenotype of our RIP-LIGHT-NOD
mice may result from the dual function of LIGHT in cell
recruitment via LTbR signaling and T cell costimulation
via HVEM, on an autoimmune prone background.
Our study demonstrates that subsequent to the early
initial priming in the PDLN, activated autoreactive cells
expressing LIGHT migrate to the peri-insular site to cre-
ate a TLO. By the expression of chemokines and adhe-
sion molecules downstream of LTbR and costimulation
via HVEM, naive T cells are recruited and activated.
The LIGHT expression that results from further T cell ac-
tivation in situ forms a positive loop that becomes self-
sustaining and chronic. Such TLOs sufficiently and nec-
essarily induce IDDM and can replace the draining LN by
directly recruiting and activating naive diversified T cells
into the targeted tissue, ultimately leading to the rapid
development of IDDM in the background of autoim-
mune-prone mice. This important positive feedback
loop is necessary for the induction of the chronic dis-
ease as the absence of the tertiary structure, as such
in young NOD mice, failed to develop the disease even
with priming unhindered in the DLN and large number
of autoreactive T cells. It is only with the transfer of naive
tg cells into old NOD mice manifesting TLO that priming
took place in situ, thus making disease induction possi-
ble. Resolution of severe insulitis by LTbR-Ig treatment
suggests that the migration of inflammatory cells into
the islets is a dynamic process. Interference with this
dynamic process may reduce inflammation, prevent-
ing further activation of autoreactive T cells and tissue
damage.
Experimental Procedures
Mice
NOD and BDC2.5 mice were purchased from Jackson Laboratories
(Bar Harbor, ME). The mice were maintained under specific patho-
gen-free conditions. Animal care and use were in accordance with
institutional and National Institutes of Health (NIH) guidelines. NOD
mice used in this manuscript were female unless otherwise stated.
BDC2.5 mice were 6–10 weeks old. All animals were maintained
and experiments were performed according to guidelines set forth
by the institutional animal care and use committee (IACUC) at the
University of Chicago.
Generation of RIP-LIGHT-NOD Tg Mice
A PCR fragment encoding the full-length murine LIGHT was gener-
ated with pcDNA-LIGHT (generated in our lab) as the template and
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508inserted into the RIP transgenic vector at ClaI site, which contains
the rat insulin II promoter (RIPII), polyadenylation site, and the first
intron of the rat insulin gene (a gift from Dr. Doug Hanahan, UCSF).
The RIP-LIGHT-NOD Tg vector was cut by NotI and SalI, and NotI/
SalI fragment was purified and used for microinjection. Microinjec-
tion of the transgene into NOD mice was performed in the transgenic
facility at Jackson Laboratory. The primers used for subcloning of
LIGHT into RIP transgenic vector were RIP-LIGHT-NOD1: 50-TATA
TCGATATGGAGAGTGTGGTACAGCC-30; RIP-LIGHT-NOD2: 50-TAT
ATCGATTCAGACCATGAAAGCTCCGA-30. Tg founder mice were
genotyped by Southern blot as described previously (Wang et al.,
2001). The genotyping primers are RIP-forward: 50-CAACCCTGACT
ATCTTCCAGG-30; RIP-LIGHT-NOD2: 50-TATATCGATTCAGACCAT
GAAAGCTCCGA-30.
Reagents
The generation and production of recombinant LTbR-human Ig and
HVEM-Ig has been previously described (Browning et al., 1997; Wu
et al., 1999). Human Ig was obtained from Biogen (Boston, MA) or
Sigma (St. Louis, MO). Antibodies to MAdCAM-1 (MECA367), CD3,
Thy1.2, and B220 were purchased from Pharmingen (San Diego,
CA), and anti-insulin was from Dako Corp. (Carpinteria, CA). Anti-
LTb antibody is a gift from Jeff Browning (Biogen idec, Boston, MA).
LTbR-Ig, HVEM-Ig, Anti-LTb Treatment and Measurement
of Blood Glucose
NOD mice were given 100 mg of fusion protein or antibody once
a week for 3 weeks or as indicated. Blood glucose concentration
was measured with SureStep strips (Johnson-Johnson, Milpitas,
CA). Animals were considered diabetic after two consecutive mea-
surements ofR250 mg/dl of glucose.
Adoptive Transfer
Recipient NOD mice (6–7) were irradiated with 6 Gy (172 rad/min)
with a 137Cs irradiator. 2 hr later, the mice were injected intravenously
with 2 3 107 splenocytes from diabetic NOD mice in 0.2 ml PBS
followed by i.p. injection with 100 mg of LTbR-Ig, anti-MAdCAM-1,
or control human Ig. For BDC2.5 transfer experiments, recipient
NOD mice (varying ages depending in experiment) were irradiated
6 Gy as mentioned above. The following day, mice were transferred
with CFSE labeled 6- to 10-week-old BDC2.5 cells (2 3 107 spleno-
cytes) intravenously. Blood glucose was monitored weekly.
Histology and Immunohistochemistry
10-week-old NOD mice were treated as above. Pancreatic tissue
was collected 1 week after the last treatment and fixed in 10% buff-
ered formalin for hemotoxylin and eosin staining and scoring as pre-
viously described (Wu et al., 2001), or the pancreata and spleen were
frozen at 270C in OCT compound for immunohistochemical stain-
ing with CD3 (L363-29B), MAdCAM-1 (MECA367), anti-insulin (Dako
Corp.), B220, or species- and isotype-specific nonreactive control
mAbs, followed by biotinylated rabbit anti-rat or goat anti-hamster
secondary antibody (Vector Laboratories, Burlingame, CA) and
then with streptavidin-HRP complex (Vector Laboratories). For T
and B cell zone staining, pancreas sections were incubated with
Thy1.2-biotin and B220-FITC followed by streptavidin-AP (Vector
Laboratories) and anti-FITC-HRP (Dako Corp.). Color was devel-
oped by Vector blue kit (for AP) or Vector DAB kit (for HRP). BrdU,
immunohistochemical staining was performed under manufac-
turer’s instructions (Pharmingen). Mice were injected with 100 mg
of BrdU via i.p. once, and then after 24 hr pancreas tissue was
harvested.
Adoptive Transfer of CFSE-Labeled Cells
and Immunofluorescence Staining
BDC2.5 splenocytes were resuspended in PBS at a concentration of
1.8 3 107 cells/ml and incubated with 10 mM of CFSE (Molecular
Probes Inc., Eugene, OR) for 30 min at 37C and then quenched
with equal volume of FCS and washed three times with PBS. Cells
were i.v. injected at 20 3 106 cells/mouse. At various time points
(48–96 hr post transfer depending on experiment or as indicated),
spleen, mesenteric LN, pancreatic draining LN, and islets were iso-
lated for analysis of CFSE dilution on Vb4+CD4+ gated population by
flow cytometry. To visualize CFSE-labeled cells in situ, pancreatictissues were frozen at 270C in OCT. Cryostat sections 6 mm in
thickness were incubated overnight with guinea pig anti-insulin
(Dako Corp.), then were incubated for 1 hr with biotinylated goat
anti-guinea pig (Vector Laboratories) followed by a 1 hr incubation
with streptavidin-PE-Cy5.
Pancreatic LN Ablation
Two of the pancreatic LNs were removed under a dissection micro-
scope as previously described (Gagnerault et al., 2002).
Islet Isolation
Pancreata were perfused in situ through the common bile duct with
collagenase P (0.375 mg/ml; Roche Corp., Basel, Switzerland) and
incubated at 37C for 10 min. Islets were released from the pan-
creata by gentle shaking. After being washed twice with Hank’s bal-
anced salt solution (HBSS), islets were further purified on discontin-
uous Ficoll gradients. After centrifugation, the islets were harvested
from the 1.096/1.069 gradient interface, washed twice in HBSS, and
collected under the microscope.
Real-Time RT-PCR
Pancreatic RNA was purified with TRIzol (Invitrogen Life Technolo-
gies) and RNA easy kit (Qiagen) according to the instructions pro-
vided by the manufacturers. cDNA was synthesized and subject to
real-time PCR as described previously (Anders et al., 2005; Lo
et al., 2003). Each cDNA sample was amplified in duplex for LIGHT
or SLC and GAPDH with the TaqMan Universal PCR master mixture
according to the manufacturer’s instructions (PE Applied Biosys-
tems, Foster City, CA).
Supplemental Data
One Supplemental Figure can be found with this article online at
http://www.immunity.com/cgi/content/full/25/3/499/DC1/.
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